Johnson & Johnson seeks U.S. FDA approval for Caplyta in bipolar mania, marking fifth potential indication
JNJ•Johnson & Johnson is seeking U.S. FDA approval for Caplyta to treat bipolar mania, which would be its fifth potential indication.
1. Approval sought
Johnson & Johnson is seeking U.S. FDA approval for Caplyta in bipolar mania, marking a fifth potential indication.




